Does Cediranib With Paclitaxel or Cediranib and Olaparib Treat Advanced Endometrial Cancer Better Than Paclitaxel?

  • days left to enroll
  • participants needed
  • sponsor
    University of Manchester
Updated on 23 January 2021
renal function
measurable disease
cytotoxic chemotherapy
neutrophil count
liver metastasis
recurrent disease
ovarian cancer
platinum-based chemotherapy
endometrial carcinoma
recurrent endometrial cancer


The COPELIA trial is evaluating two new tablet medications in endometrial cancer for the first time. It will include 129 women aged 16 years or older with advanced endometrial cancer whose cancer has worsened after their initial chemotherapy treatment. Participants will be allocated at random to one of three groups:

  1. The first group (Arm 1) will receive a standard (routine) treatment for patients with endometrial cancer known as paclitaxel. This is a chemotherapy drug that is routinely used to treat patients with different cancers including ovarian, breast, lung and endometrial cancer. Paclitaxel works by stopping the growth of cancer cells.
  2. The second group (Arm 2) will receive the standard paclitaxel treatment once a week in addition to a new drug called cediranib. Cediranib is a tablet medication and works by blocking new blood vessel formation. Cediranib has been tested in women with endometrial cancer before but not alongside chemotherapy treatment.
  3. The third group (Arm 3) will receive two new tablet medications, cediranib and olaparib. Olaparib works by preventing cancer cells repairing DNA effectively. The use of olaparib and cediranib together has been shown to be effective in a common type of ovarian cancer but has not been evaluated as a treatment for endometrial cancer before.

The main objectives of the COPELIA trial are to work out:

  1. Whether the two new treatments, cediranib-paclitaxel (Arm 2) and cediranib-olaparib (Arm
  2. are more effective at controlling endometrial cancer than standard paclitaxel chemotherapy (Arm 1)
  3. Whether the two new treatments cause more or fewer side-effects than standard chemotherapy
  4. How each of these treatments impact on the daily life of women receiving the treatment by asking trial participants to regularly complete quality of life questionnaires
  5. Whether we can learn how these treatments work in women with endometrial cancer by taking some additional blood tests for research. In women allocated to Arm 3 (and only at participating hospitals), we will ask permission to take a small biopsy from an area of cancer before they start treatment to see if we can predict which women may benefit from olaparib.


COPELIA is a phase II, randomised, three-arm open-label trial which will recruit 129 women aged 16 years or older, with advanced endometrial cancer who require further treatment after their initial chemotherapy treatment. Potential participants will be recruited from the hospital setting.

Participants will be allocated to one of the following three trial arms on a 1:1:1 basis using centralised internet randomisation, stratified for prognostic factors:

Arm 1: (Control Arm): Paclitaxel 80 mg/m2 administered on days 1, 8 and 15 of a 28-day cycle for up to 6 cycles.

Arm 2: Cediranib 20 mg once daily for 28 days given with weekly paclitaxel 80 mg/m2 administered on days 1, 8 and 15 of a 28-day cycle for up to 6 cycles. Participants with stable disease, partial response or complete response at 6 months as determined by RECIST v1.1 will be eligible to continue treatment with single agent cediranib once daily until disease progression.

Arm 3: Cediranib 20 mg once daily with olaparib 300 mg twice daily, continuously on a 28 day cycle for up to 6 cycles. Participants with stable disease, partial response or complete response at 6 months as determined by RECIST v1.1 will be eligible to continue treatment with both olaparib and cediranib until disease progression.

Randomisation will be balanced for histological subtype and the number of chemotherapy regimens for metastatic disease.

Recruitment to the trial is expected to take 30 months. The total duration of the trial is expected to be 55 months. Participants will receive initial trial treatments for up to six months as long as they remain progression free. As mentioned above, participants in the experimental arms may continue treatment with cediranib/olaparib beyond the six months, and beyond the end of the trial, if they remain progression free. The trial will end once all participants have met at least one of the criteria: completed 12 months' follow-up (including treatment), withdrawn from follow-up, been lost to follow-up, experienced disease progression, or died. Participants consent for their medical notes to be reviewed at later dates if required to obtain data such as overall survival.

The trial has a multi-arm-multi-stage (MAMS) design. The appropriate sample size was calculated for this MAMS design, which allows one (or both) ineffective experimental arms to be dropped following a planned interim analysis after 60 participants have been assessed at three months.

Condition Endometrial Carcinoma, Uterine Cancer, Carcinosarcoma, Sarcoma, Sarcoma (Pediatric), Endometrial Cancer, Soft Tissue Sarcoma
Treatment Paclitaxel, olaparib, Cediranib
Clinical Study IdentifierNCT03570437
SponsorUniversity of Manchester
Last Modified on23 January 2021


Yes No Not Sure

Inclusion Criteria

Histologically confirmed advanced or recurrent endometrial carcinoma or carcinosarcoma
Aged >16 years
All participants must have received at least one prior line of platinum-based chemotherapy (either in the adjuvant or recurrent disease setting). In addition, ONE of the following must apply
have disease recurrence/ progression within 18 months of completing adjuvant chemotherapy and have received no cytotoxic chemotherapy for recurrent/ progressive endometrial cancer
\. have received one or two prior lines of cytotoxic chemotherapy for
recurrent/ progressive endometrial cancer (not counting adjuvant treatment)
\. Dose-dense weekly paclitaxel is an appropriate treatment option
\. Ability to provide written informed consent that includes genetic research
on tissue derived from biopsies and biomarker research. (If a participant
declines to participate in optional exploratory genetic research or the
optional biomarker research, there will be no penalty or loss of benefit to
the participant. The participant will not be excluded from other aspects of
the study)
\. Willing and able to comply with the trial visits and undergo treatment as
\. ECOG Performance Status 0-1
\. Life expectancy greater than 16 weeks
\. Measurable disease by RECIST v1.1 including at least one not previously
irradiated lesion that is 10 mm in the longest diameter (lymph nodes must have
short axis 15 mm) as determined by CT
\. Adequate haematological function: Hb 90.0 g/l with no requirement for
blood transfusion in the last 28 days, neutrophils 1.5 x 109/l, platelets 100
x 109/l; coagulation: INR <1.4 (unless therapeutically anti-coagulated) and
APPT ratio <1.4
\. Adequate liver function: bilirubin 1.5 x ULN, transaminases ALT and AST
5x ULN. (AST or ALT <5x ULN allowed in the presence of parenchymal liver
\. Adequate renal function defined as calculated creatinine clearance using
modified Wright or Cockcroft-Gault formula 51 ml/min or measured radioisotopic
GFR 51ml/min
\. Negative or trace proteinuria reading on urine dipstick. Patients with 1+
proteinuria on dipstick must have 1+ proteinuria on consecutive dipstick taken
no less than 1 week later. Patients with 2+ proteinuria on dipstick must have
hour urinary protein excretion 1 g
\. Adequately controlled thyroid function, with no symptoms of thyroid
\. Ability to swallow oral medication (tablets)
\. Willing to stop taking herbal supplements, and (if allocated to Arm 3)
willing to not consume grapefruit or grapefruit juice, during the treatment
period and for 30 days after end of trial treatment

Exclusion Criteria

Prior treatment with dose-dense weekly paclitaxel
Uncontrolled brain metastases or seizures. A scan to confirm the absence of brain metastases is not required
Known positivity for hepatitis B, hepatitis C or HIV due to the risk of transmitting the infection through blood or other body fluids and potential for reactivation during treatment
Resting ECG with QTc > 470 ms on 2 or more time points within a 24 hour period or family history of long QT syndrome
Concomitant use of known strong CYP3A inhibitors (eg. itraconazole, telithromycin, clarithromycin, protease inhibitors boosted with ritonavir or cobicistat, indinavir, saquinavir, nelfinavir, boceprevir, telaprevir) or moderate CYP3A inhibitors (eg. ciprofloxacin, erythromycin, diltiazem, fluconazole, verapamil). The required washout period prior to starting olaparib is two weeks
Concomitant use of known strong CYP3A inducers (eg.phenobarbital,enzalutamide, phenytoin, rifampicin, rifabutin, rifapentine, carbamazepine, nevirapine and St John's Wort) or moderate CYP3A inducers (eg. bosentan, efavirenz, modafinil). The required washout period prior to starting olaparib is 5 weeks for enzalutamide or phenobarbital and 3 weeks for other agents
Pregnant or lactating. Pregnancy status in women of child bearing potential will be confirmed via a serum or urine pregnancy test prior to randomisation, monthly during the treatment period, and at the end of treatment assessment
Of child bearing potential AND not willing to ensure they use effective contraception throughout the treatment period and for six months following the end of treatment. Acceptable methods of contraception are
true sexual abstinence (when this is in line with the preferred and usual lifestyle of the participant) ii. a combination of male condom plus one of
vasectomised sexual partner, with participant assurance that partner received post-vasectomy confirmation of azoospermia
Tubal occlusion
Intrauterine device provided coils are copper-banded
Etonogestrel implants (eg, Implanon, Norplant)
Normal and low dose combined oral pills
Hormonal shot or injection (eg, Depo-Provera)
Intrauterine system device (eg, levonorgestrel-releasing intrauterine system -Mirena)
Norelgestromin/ethinyl estradiol transdermal system
Intravaginal device (eg, ethinyl estradiol and etonogestrel)
Cerazette (desogestrel). Cerazette is currently the only highly efficacious progesterone based pill
Side effects of previous treatments have not resolved to grade 1 or less, with the exception of alopecia that is considered related to cytotoxic chemotherapy
Radiotherapy, chemotherapy, surgery or tumour embolisation within 28 days before the first dose of IMP
Additional concurrent anti-cancer therapy
Causes of malabsorption, e.g. uncontrolled diarrhoea or poorly controlled stoma
Bowel obstruction, fistulae, impending fistulation seen on radiological imaging, or extensive rectosigmoid involvement by cancer
Inadequately controlled hypertension, defined as 150/90 mmHg
Prior or concurrent therapy with a PARP or VEGF inhibitor
Known hypersensitivity to olaparib, cediranib or any of the excipients of the products
Known hypersensitivity to paclitaxel that in the opinion of the investigator would prevent administration of a weekly paclitaxel regimen
Exposure to an investigational agent within 30 days or 5 half-lives (whichever is the longer) prior to enrolment
Considered a poor medical risk due to a serious, uncontrolled medical disorder, non-malignant systemic disease or active, uncontrolled infection. Examples include, but are not limited to, uncontrolled ventricular arrhythmia, recent (within 3 months) myocardial infarction, uncontrolled major seizure disorder, unstable spinal cord compression, superior vena cava syndrome, extensive interstitial bilateral lung disease on High Resolution Computed Tomography (HRCT) scan or any psychiatric disorder that prohibits obtaining informed consent
Myelodysplastic syndrome (MDS), acute myeloid leukaemia (AML) or features suggestive of MDS/AML
Other malignancy within the last 5 years except: adequately treated non-melanoma skin cancer, curatively treated in situ cancer of the cervix, ductal carcinoma in situ (DCIS), or other solid tumours including lymphomas (without bone marrow involvement) curatively treated with no evidence of disease for 5 years
Prior allogeneic bone marrow transplant or double umbilical cord blood transplantation
Clear my responses

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Preferred Language
Other Language
Please verify that you are not a bot.

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note